Related Experiment Video
Updated: Sep 26, 2025
14:14
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
Published on: August 12, 2018
9.0K
Subthalamic nucleus deep brain stimulation driven by primary motor cortex γ2 activity in parkinsonian monkeys
Olivier Darbin1,2, Nobuhiko Hatanaka3,4, Sayuki Takara3,4,5
1Division of System Neurophysiology, National Institute for Physiological Sciences, Okazaki, Aichi, Japan. olivieredarbin@gmail.com.
Scientific Reports
|April 21, 2022
Summary
Adaptive deep brain stimulation (aDBS) using primary motor cortex gamma-2 band activity in parkinsonian monkeys offers comparable symptom relief to constant DBS (cDBS) but with significantly reduced electrical charge. This brain-machine interface approach shows promise for more efficient Parkinson
Area of Science:
- Neuroscience
- Biomedical Engineering
- Neuromodulation
Background:
- Subthalamic nucleus (STN) deep brain stimulation (DBS) is effective for Parkinson's disease symptoms but can cause side effects.
- Adaptive DBS (aDBS) offers potential for reduced side effects by modulating stimulation, yet its clinical efficacy requires further investigation.
Purpose of the Study:
- To develop and test a brain-machine interface for adaptive DBS (aDBS) in parkinsonian monkeys.
- To evaluate the effectiveness and charge efficiency of aDBS modulated by primary motor cortex (M1) gamma-2 band activity compared to constant DBS (cDBS).
Main Methods:
- A brain-machine interface was developed to modulate STN-DBS parameters based on M1 local field potential (LFP) gamma-2 band activity (80-200 Hz) in parkinsonian monkeys.
- Two monkeys were rendered parkinsonian and performed a motor task, with their performance compared under aDBS, cDBS, and DBS-OFF conditions.
- Stimulation parameters were modulated by M1 gamma-2 band activity, which increased during movements in parkinsonian monkeys.
Main Results:
- Both aDBS and cDBS significantly improved reaction and movement times compared to DBS-OFF.
- The M1 gamma-2 band activity modulated aDBS parameters, including pulse interval, amplitude, and dispersion.
- aDBS delivered approximately two-thirds of the electrical charge compared to cDBS while achieving comparable clinical benefits.
Conclusions:
- M1 gamma-2 band activity-based aDBS is an effective therapeutic strategy for parkinsonism in a preclinical model.
- This adaptive approach offers comparable clinical benefits to conventional DBS but with significantly lower energy consumption.
- The findings support the potential of aDBS for more efficient and potentially safer Parkinson's disease treatment.
